We conducted a study of 155 patients with allergic rhinitis who prematurely discontinued subcutaneous allergen immunotherapy to determine the reasons for their discontinuation. Th e most commonly cited factor, which was cited by 62 patients (40.0%), was the issue of cost-specifi cally, inadequate or nonexistent insurance coverage. Studies have shown that subcutaneous allergen immunotherapy is more cost-eff ective than pharmacologic treatment for patients with allergic rhinitis. Th erefore, improved insurance coverage for this treatment of proven effi cacy would not only improve quality of life, it would also be economically benefi cial to the health care system in general.